Cas:39204-47-2 2-(Chloromethyl)pyrazine manufacturer & supplier

We serve Chemical Name:2-(Chloromethyl)pyrazine CAS:39204-47-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-(Chloromethyl)pyrazine

Chemical Name:2-(Chloromethyl)pyrazine
CAS.NO:39204-47-2
Synonyms:2-(Chloromethyl)pyrazine;Pyrazine, (chloromethyl)-;Pyrazine, 2-(chloromethyl)-;3-Butynoicacid,2-[[(1,1-dimethylethoxy)carbonyl]amino]-,methylester(9CI)
Molecular Formula:C5H5ClN2
Molecular Weight:128.560
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:202.9±25.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.534
PSA:25.78000
Exact Mass:128.014130
LogP:-0.01

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-(Chloromethyl)pyrazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Butynoicacid,2-[[(1,1-dimethylethoxy)carbonyl]amino]-,methylester(9CI) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyrazine, (chloromethyl)- Use and application,Pyrazine, (chloromethyl)- technical grade,usp/ep/jp grade.


Related News: But Vietnam then partly eased its ban, allowing flights from Hong Kong and Macau to continue, aviation authorities said. 2-(Chloromethyl)pyrazine manufacturer The New York Times said that the batches being discarded amount to around 60 million doses, citing people familiar with the matter. 2-(Chloromethyl)pyrazine supplier Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. 2-(Chloromethyl)pyrazine vendor Aduhelm, however, is in a different league in terms of the number of potential patients and cost to the healthcare system. 2-(Chloromethyl)pyrazine factory International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation.